Vivus, a go-it-alone marketer with flailing obesity drug Qsymia, is discovering the joys of buddying up.
After rolling out its weight-loss drug Qsymia solo, a move that spurred plenty of shareholder discontent, Vivus is taking marketing partnerships for erectile dysfunction drug Stendra seriously. Thursday, it announced a deal with Sanofi that covers licensing and commercialization in emerging markets.
Vivus investors are still waiting for the company to nail down the marketing partner the company's leadership promised would help turn things around for weight-loss drug Qsymia. In the meantime, the company has inked a second marketing deal for erectile dysfunction drug Stendra.
The company's rebel shareholder sued Vivus for postponing its annual meeting, accusing the board of directors of stalling to keep themselves in office.
Vivus may still lack a marketing partner for Qsymia. But it has signed up some help rolling out its new erectile dysfunction treatment Stendra.
It's a good thing that the new erectile-dysfunction drug Stendra works more quickly than its developer does. Vivus may finally get the drug onto the market, thanks to new data showing that Stendra works in 15 minutes, rather than 30 as previously recommended.
Vivus finally won an approval from FDA: The agency has blessed its erectile dysfunction treatment, Stendra.
Vivus has won its first drug approval. The FDA issued word this afternoon that it had stamped its OK on Stendra (avanafil), an erectile dysfunction treatment designed to spur a quicker response for men.